# Sermorelin References: The Cited GHRH(1-29) Research Record

> Sermorelin references: the full citation list behind this digest — PubMed-indexed GHRH(1-29) and GHRH-analog studies with DOIs, PMIDs, and trial identifiers.

Every quantitative claim on this site maps to a numbered entry below — PubMed-indexed studies with DOIs, PMIDs, and trial identifiers.

## How to read this list

The sermorelin references below are the complete source set for this digest. In-text markers ([1], [2], and so on) resolve to these entries. Where a finding concerns a stabilized GHRH analog (tesamorelin) rather than GHRH(1-29) itself, both the entry and the text that cites it say so — the distinction is load-bearing across this site. Each citation carries a DOI or PubMed link, and trial entries carry their ClinicalTrials.gov identifier where applicable, so any claim on these pages can be traced to its primary source. The list spans the foundational pharmacokinetic and pediatric work of the early 1990s through a 2025 Nature Reviews Endocrinology synthesis of GHRH and its analogues.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (SMART trial, NCT00257712) https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
[8] Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292(2):210-218. https://pubmed.ncbi.nlm.nih.gov/15249570/
[9] Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. https://pubmed.ncbi.nlm.nih.gov/23015655/
[10] Utz AL, et al. The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors. Mediators Inflamm. 2010;2010:434562. https://pubmed.ncbi.nlm.nih.gov/20150954/
[11] Falutz J. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. https://pubmed.ncbi.nlm.nih.gov/22298602/
[12] Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9005976/
[13] Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[14] Vance ML, Evans WS, Kaiser DL, et al. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships. Clin Pharmacol Ther. 1986;40:627-33. https://pubmed.ncbi.nlm.nih.gov/3096623/
[15] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/

---

The sermorelin record filed cell by cell on a research board — every GH and IGF-1 figure carried back to its study, the body-composition evidence marked as tesamorelin where it belongs, and the empty long-term-safety cell left openly unfilled; no clinic behind the board and nothing here dosed, dispensed, or sold.